Survivorship starts the moment you find out you are at risk.
Unlock the power of EARLY CANCER DETECTION
Testing via Liquid Biopsy for early detection, management & monitoring of Cancer
Liquid biopsy has emerged as a promising tool for detecting cancer-related abnormalities in a minimally invasive manner. It involves the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other biomarkers present in the blood.
The power of liquid biopsy lies in its ability to detect cancer at an early stage, when it is most treatable, then monitor for treatment response, resistance and adjustments as cancer evolves.
DATAR CANCER GENETICS our partner in early cancer detection, diagnosis and treatment management.
A NON-INVASIVE way to Detect Cancer
DATAR TRUCHECK INTELLI™
1
Early Detection allows a person to take control of their health and seek appropriate medical care if any abnormalities are found.
Studies show that early detection improves outcomes for both eradication and effective control of cancer. This is because Early-stage cancers are generally smaller and have not spread to nearby tissues or other parts of the body.
This makes them more amenable to surgical removal, and potentially less invasive treatment options.
DATAR eXACTA 360™
Encyclopedic Interrogation of Cancer
Identify Tumor Dynamics
2
Working to Revolutionize Cancer Care Through Innovative Solutions
Every cancer and every patient is different; consequently, treatments that are not customized for each patient have lesser chances of succeed. Additionally, cancer cells are known to evade and survive treatments leading to gradual ineffectiveness and recurrence.
Our solutions offer deep genomic and cellular analysis of a patient’s cancer that can help identify personalized treatment strategies.
LEARN MORE
DATAR chemo-scale™
ELIMINATE GUESSWORK
Chemo - resistance Profiling of Circulating Tumor Associated Cells
3
Chemo-scale™ evaluates in vitro chemo-resistance in CTCs, which are known to be present (and detected ubiquitously) in almost all solid organ tumors, irrespective of age, gender, primary organ, subtype, grade, stage or treatment status.
Since CTACs include CTCs as well as TACs which play an important role in sustaining a malignancy, determination of chemo-resistance in CTACs has high correlation with tumor tissues. Datar's prior acclaimed clinical studies have shown that CTAC based determination of in vitro chemo-resistance has high concordance with tumor tissue-based determinations as well as with clinical outcomes.
FILL OUT THE FORM BELOW TO GET IN TOUCH
PERSONALIZE, PLAN AND MONITOR CANCER TREATMENT
Oncotarget: RESILIENT Trial Results
Published on September 24, 2019 the “Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial” Datar Cancer Genetics Limited.
© calmovercancer.COM | ALL RIGHTS RESERVED | TERMS & CONDITIONS | MEDICAL DISCLAIMER